



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :  C08J 9/18, A41K 9/16 // C08L 67/04		A1	(11) International Publication Number: <b>WO 91/09079</b>  (43) International Publication Date: 27 June 1991 (27.06.91)
(21) International Application Number: PCT/EP90/01895  (22) International Filing Date: 13 November 1990 (13.11.90)			(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).
(30) Priority data: 8928250.3 14 December 1989 (14.12.89) GB			Published <i>With international search report.</i>
(71) Applicant: FARMITALIA CARLO ERBA S.R.L. [IT/IT]; Via Carlo Imbonati, 24, I-20159 Milan (IT).			
(72) Inventors: DE PONTI, Roberto ; Via degli Astri, 22, I-20147 Milan (IT). TORRICELLI, Clara ; Via M.A. Colonna, 38, I-20149 Milan (IT). MARTINI, Alessandro ; Via Tranquillo Cremona, 29, I-20145 Milan (IT). LARDINI, Ercole ; Via Rossini, 14A, I-20090 Pieve Emanuele (IT).			
(54) Title: USE OF SUPERCRITICAL FLUIDS TO OBTAIN POROUS SPONGES OF BIODEGRADABLE POLYMERS			
(57) Abstract			
<p>A method of preparing a biodegradable porous matrix is disclosed, which comprises contacting a biodegradable polymer with a supercritical fluid in a chamber and subsequently reducing the pressure in the chamber in a sharp step. The matrix thus produced has a high porosity and may be used in a variety of pharmaceutical applications such as for surgical implantation or in controlled-release drug delivery systems.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CI	Côte d'Ivoire	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		

- 1 -

USE OF SUPERCRITICAL FLUIDS TO OBTAIN POROUS

SPONGES OF BIODEGRADABLE POLYMERS

The present invention relates to the preparation of porous materials made of biodegradable polymers.

5        Polymeric matrices which are both porous and biodegradable are useful in a variety of pharmaceutical applications, such as controlled release drug delivery and surgical implantation. For example, a bone graft substitute comprising a biodegradable porous polymer is  
10      described in GB-A-2215209, whilst a controlled drug delivery system comprising porous biodegradable polymeric microspheres is discussed by Sato et al in Pharm.Research, Vol.5, No.1, pp 21-30, 1988. A subcutaneously implanted porous polyvinyl alcohol sponge used to treat rats with  
15      basic fibroblast growth factor (bFGF) is reported by McGee et al in J.Surgical Research 45, 145-153 (1988), which treatment is observed to accelerate wound healing in the rats.

A convenient new method of making a porous biodegradable  
20      polymer has now unexpectedly been found. Accordingly, the present invention provides a method of preparing a biodegradable porous polymer matrix which comprises contacting a biodegradable polymer with a supercritical fluid in a chamber and subsequently reducing the pressure  
25      in the chamber to a value below the critical pressure of the fluid in a sharp step.

- 2 -

By supercritical fluid is meant a gas or liquid above its critical point. The critical point of a substance is the point on a state diagram of temperature plotted against pressure at which there ceases to be a dividing line

5 between the gaseous and liquid states. At the critical point physical properties of the liquid and gaseous states, in particular the densities, are identical. The temperature and pressure values at the critical point may be termed the critical conditions and are constant for a  
 10 given fluid. The critical conditions for a variety of fluids are listed in Table 1 which follows.

TABLE 1  
 Critical Conditions for Various Gases and Liquids.

15		Critical Temperature	Critical Pressure	
		°C	kPa	(atm)
	Carbon Dioxide	31.1	7376	(72.8)
	Ethane	32.3	4884	(48.2)
	Ethylene	9.3	5036	(49.7)
20	Propane	96.7	4246	(41.9)
	Propylene	91.9	4620	(45.6)
	Cyclohexane	280.3	4073	(40.2)
	Isopropanol	235.2	4762	(47.0)
	Benzene	289.0	4894	(48.3)
25	Toluene	318.6	4114	(40.6)
	p-Xylene	343.1	3516	(34.7)
	Chlorotrifluoromethane	28.9	3921	(38.7)
	Trichlorofluoromethane	198.1	4408	(43.5)
	Ammonia	132.5	11280	(111.3)
30	Water	374.2	22050	(217.6)

- 3 -

A supercritical region may be defined in the state diagram of a substance, as illustrated in Figure 1 of the accompanying drawings. A fluid is in a supercritical condition when subjected to temperature and pressure values 5 falling within this region.

Any supercritical fluid, including any of those listed above in Table 1, may be used in the process of the present invention. Carbon dioxide, at a pressure of at least 7376 kPa and a temperature of at least 31.1°C, is a preferred 10 example.

The biodegradable polymer is suitably brought into contact with the supercritical fluid in the chamber of any standard supercritical extractor or any suitable device, examples being the extractor supplied by Muller Extract 15 Company GmbH, the Sample Preparation Accessory supplied by Milton Roy, or the apparatus shown in Figure 2. In operation, the biodegradable polymer is loaded in the extraction chamber of the supercritical extractor and the supercritical fluid is then applied for a time sufficient 20 to allow supercritical fluid to penetrate the mass of the polymer by diffusion, and possibly dissolve the mass. The time needed will vary according to the fluid and the particular supercritical conditions used, and also according to the amount of material to be penetrated or 25 dissolved. The greater the mass of polymer, the longer will be the time needed for the process to be completed,

- 4 -

assuming all other parameters controlling the process to remain constant. For a mass of polymer of from 1 to 50g, the time is typically of the order of from 3 minutes to 2 hours. For example, when carbon dioxide is the 5 supercritical fluid it is suitably applied to this mass of material for 45 minutes under conditions of 32°C and 7600 kPa (75 atm), or for 1 hour at 32°C and 15200 kPa (150 atm).

Once the process is complete, the pressure inside the 10 supercritical chamber is reduced in a sharp step. This means that the pressure in the chamber is brought to a value below the critical pressure of the fluid, typically in a period of from 0 to 3 minutes. Preferably the period is from 5 to 30 seconds. The pressure may be reduced in 15 this sharp step to any given value below the critical pressure of the fluid; generally it is between the critical pressure and ambient pressure. If this given value is higher or lower than ambient pressure, the pressure in the chamber is restored to ambient subsequently. In one 20 embodiment of the invention the pressure in the chamber is reduced to ambient pressure in the sharp step. By ambient pressure is meant a pressure of about 101.325 kPa (1 atmosphere).

The sharp pressure reduction contributes towards 25 achieving the desired porosity in the material obtained. The greater the difference between the operating pressure

- 5 -

of the supercritical chamber and ambient pressure, the higher is the porosity of the resulting product. The operating temperature of the supercritical chamber can also be adjusted to modify the product porosity; the higher the 5 supercritical temperature employed, the higher is the porosity achieved.

During the process of the invention the operating temperature in the supercritical chamber is controlled. Any suitable control means may be used, for example a 10 water-recirculating bath such as is employed in the Muller extractor, or an air stream such as is employed in the Sample Preparatory Accessory (SPA) apparatus supplied by Milton Roy. The particular operating (supercritical) temperature selected in a given situation will depend 15 partly upon the solubility of the biodegradable polymer in the supercritical fluid since, at a given pressure, this solubility will vary with temperature. It will also partly depend upon the diffusion coefficient of the supercritical fluid in the polymer since, at a given pressure, this 20 coefficient will vary with temperature. As previously indicated, the particular operating temperature employed affects the physical state of the polymer which is achieved.

It is sometimes desirable to operate at the lowest 25 temperature compatible with the solubility of the polymer in the supercritical fluid, and/or with permeation of the

- 6 -

supercritical fluid into the polymer under given supercritical pressure conditions. This may be, for example, when a thermally unstable active ingredient is contained in the polymer. At other times, however, this 5 consideration does not apply and a higher operating temperature may be selected.

Any biodegradable polymer may be used as starting material in the process of the invention, suitable examples including polylactides. The term polylactide designates 10 the general class of polymers which can be prepared from one or more of the following monomers: 3-propiolactone, tetramethylglycolide,  $\alpha$ -butyrolactone, 4-butyrolactone, pivalolactone, and intermolecular cyclic esters of  $\alpha$ -hydroxy butyric acid,  $\alpha$ -hydroxyisobutyric acid, 15  $\alpha$ -hydroxyvaleric acid,  $\alpha$ -hydroxyisovaleric acid,  $\alpha$ -hydroxycaproic acid,  $\alpha$ -hydroxy- $\alpha$ -ethylbutyric acid,  $\alpha$ -hydroxyisopcaproic acid,  $\alpha$ -hydroxy-3-methylvaleric acid,  $\alpha$ -hydroxyheptanoic acid,  $\alpha$ -hydroxyoctanoic acid,  $\alpha$ -hydroxydecanoic acid,  $\alpha$ -hydroxymyristic acid, 20  $\alpha$ -hydroxystearic acid, and  $\alpha$ -hydroxylignoceric acid. It is most preferred to use lactic acid as sole monomer or lactic acid as the principal monomer with glycolic acid as the comonomer. The latter are termed poly(lactide-co-glycolide) copolymers. 25 Particularly suitable are polymers prepared from lactic acid alone, glycolic acid alone, or lactic acid and

- 7 -

glycolic acid wherein the glycolic acid is present as a comonomer in a molar ratio of 100:0 to 40:60. It is most preferred to use a poly(lactide-co-glycolide) copolymer having a molar ratio between about 80:20 and 50:50.

- 5       Poly(lactide) homopolymers, poly(glycolide) homopolymers and poly(lactide-co-glycolide) copolymers may range in size from 1,000 to 200,000 in molecular weight stated as an average ( $\overline{MW}$ ). The molecular weight of a particular
- 10      copolymer is independent of its monomeric makeup. For example, a 50:50 copolymer can have a molecular weight which falls anywhere within this range. Therefore polymers can be varied both as to their monomer composition as well as their molecular weight.
- 15      Examples of other suitable biodegradable polymers include: polyanhydrides, for example as described in US-A-4,757,128, Biomaterials 1983, Vol. 4, pages 131-133, J. Biomedical Materials Research, Vol. 19, pages 941-955 (1985), J. Biomedical Materials Research, Vol. 20, pages 51-64 (1986) or Biomaterials 1986, Vol. 7, pages 364-371; and polyacetals, polyketals and poly(orthoesters), for example as described in Polym.Sci.Technol. 1986, Vol. 34, Polymer Med. 2, pages 357-365.
- 20      The biodegradable polymeric starting material may be in the form of microspheres, pellets, a matrix of any geometrical shape, or in any other form. When microspheres

- 8 -

or any other of the aforementioned starting materials are used these may be, if desired, pre-loaded with an active ingredient so that the process of the invention yields, in one step, a porous spongy material carrying an active 5 ingredient. Microspheres of a poly(lactide-co-glycolide) copolymer or of a polylactide homopolymer are particularly suitable.

When the biodegradable polymer is in the form of microspheres, these are prepared in a conventional manner.

10 A standard method involves dispersing the biodegradable polymer in an organic solvent, a suitable example being dichloromethane, and adding a silicone oil dropwise to the dispersion with stirring. The microspheres thus obtained are then washed and hardened by treatment with a non-polar 15 hydrocarbon solvent such as pentane or heptane.

The active ingredient contained in the microspheres may be any drug used in surgery, therapy or prophylaxis.

Examples include: peptides and proteins, in particular immunomodulators such as Thymic Humoral Factor; growth 20 factors such as basic Fibroblastic Growth Factor, acid Fibroblastic Growth Factor, Epidermal Growth Factor, Human Growth Factor, Insulin Like Growth Factor, Platelet Derived Growth Factor, Nerve Growth Factor and Transforming Growth Factor; antitumorals such as BCNU or 1,3-bis(2-chloro- 25 ethyl)-1-nitrosourea, daunorubicin, doxorubicin, epirubicin, idarubicin, 4-demethoxydaunorubicin

- 9 -

3'-desamine-3'-(3-cyano-4-morpholinyl) - doxorubicin,  
4-demethoxydaunorubicin-3'-desamine-3'-(2-methoxy-4-  
morpholinyl)-doxorubicin, etoposide and teniposide;  
hormones such as LHRH and LHRH analogues; and steroideals  
5 for birth control and/or antitumoral action such as  
medroxyprogesterone acetate or megestrol acetate.

If forms of biodegradable polymer other than  
microspheres are used, such as pellets or matrices of any  
geometric shape, these may also, if desired, be pre-loaded  
10 with an active ingredient such as any of those listed  
above.

The porous biodegradable polymeric material obtained in  
accordance with the invention may be used as a surgical  
implant, for example to aid the reconstitution of tissues  
15 after surgical removal of a tumour or after trauma  
injuries. Such an implant has immediate utility in filling  
anti-aesthetic voids caused by the surgery or injury,  
giving support for newly-growing tissue which is able to  
fill the pores of the material. The biodegradable material  
20 itself, as it disintegrates in vivo, will then gradually be  
replaced by the new tissue. The time required for the  
degradation of the biodegradable material is related to the  
composition of the polymer(s), the molecular weight of the  
polymer, the relative proportions of comonomers (in the  
25 case of a copolymer(s)), and the physical state. The  
process of reconstitution of the damaged tissue is enhanced

- 10 -

if the porous polymer is loaded with a suitable growth factor such as any of those listed earlier, chosen according to the particular application.

The porous biodegradable material is also particularly 5 useful in the treatment of tumours which are not removable. In this case the material is loaded with an anti-tumour agent, such as any of those listed earlier, and implanted at the site of the tumour. An example is the treatment of the glioblastoma multiform in the brain.

10 The porosity (P) of the material produced in accordance with the invention may be calculated, in percentage terms, using the following equation:

$$P = [1 - (D1/D2)] \times 100$$

in which D1 is the apparent density of the material and D2 15 is the true density, measured by the standard method of helium piconometry. A porosity of up to as high as 74% is achieved in accordance with the invention.

Besides giving rise to a highly porous product the process of the invention has the important advantages that, 20 since it allows a non-oxidising agent to be used at a relatively low temperature (e.g. CO<sub>2</sub> above 31.1°C), it is relatively non-hazardous and non-toxic and does not cause degradation of any active ingredient contained in the biodegradable polymer starting material. In addition, it 25 is easy to carry out on a large scale and is therefore of economic importance.

- 11 -

The following Examples further illustrate the invention.

Reference Example 1: Preparation of biodegradable microspheres

2g of poly (D,L) lactide, of molecular weight 100,000  
5 and intrinsic viscosity of 1 (Boehringer Ingelheim) were dissolved in 80 ml of  $\text{CH}_2\text{Cl}_2$ . 0.8 ml of phosphate buffer (pH 7.4, I=0.1) were dispersed finely in the  $\text{CH}_2\text{Cl}_2$  phase with an Ultra-Turrax stirring turbine equipment, operating at 4000 rpm with a dispersing tool (type G45F). 60ml of  
10 silicone oil Dow Corning Fluid 200 were added dropwise under continued stirring.

The microspheres obtained were washed and hardened with  
21 of n-heptane, then desiccated under vacuum at 35°C for  
24 hours, and sieved. The microspheres obtained had a mean  
15 diameter of about 80  $\mu\text{m}$ .

The n-heptane residual content was about 17%.

Reference Example 2

The process of Reference Example 1 was carried out using poly ((D,L) lactide-co-glycolide) copolymer, having a  
20 lactide: glycolide ratio of 75:25, a molecular weight of 18000 and intrinsic viscosity of 0.8 (Boehringer Ingelheim) instead of the poly (D,L) lactide.

The n-heptane residual content was about 10%.

- 12 -

Reference Example 3

The process of Example 2 was repeated using n-pentane in place of n-heptane.

The n-pentane residual content was about 5%

5 Reference Example 4: Preparation of biodegradable microspheres loaded with an active ingredient

2g of poly (D,L) lactide of molecular weight 100,000 and intrinsic viscosity of 1 (Boehringer Ingelheim) were dissolved in 80ml of  $\text{CH}_2\text{Cl}_2$ . 200mcg of basic fibroblast

10 growth factor was dissolved in 0.8ml of phosphate buffer (pH 7.4, I=0.1) and the aqueous phase dispersed finely in the  $\text{CH}_2\text{Cl}_2$  with an Ultra-Turrax stirring turbine apparatus, operating at 4000 rpm with a dispersing tool (type G45F).

60ml of silicone oil Dow Corning Fluid 200 were added

15 dropwise under continuous stirring. The microspheres obtained were washed and hardened with 2l of n-heptane, then desiccated under vacuum at 35°C for 24 hours, and sieved.

The microspheres obtained had a mean diameter of about

20 80  $\mu\text{m}$ . The n-heptane residual content was about 17%.

EXAMPLE 1: Preparation of porous biodegradable material

1.5 g of the microspheres obtained by the process of Reference Example 1 were loaded in the extraction chamber of a supercritical extractor (Muller Extract Company GmbH).

- 13 -

CO<sub>2</sub> was applied at 15200 kPa (150 bar) and 35°C for 1 hour.

The CO<sub>2</sub> was taken from a bomb (cylinder) and loaded into the extractor. The pressure of 15200 kPa (150 bar) was applied by means of a mechanical pump. The temperature was 5 kept at 35°C during the process by means of a recirculating water bath. After 1 hour the pressure was reduced to ambient pressure in 10 seconds. The extraction chamber was opened and a spongy material was obtained.

10 The porosity of the material was determined by the equation:

$$P = [1 - (D1/D2)] \times 100$$

where D1 is the apparent density and D2 is the true density measured by helium piconometry and found to be about 76%.

The residual content of n-heptane was 100 ppm.

15 EXAMPLE 2

The process of Example 1 was repeated but using the following CO<sub>2</sub> supercritical conditions: 7600 kPa (75 bar), 32°C, 45 min.

20 The material obtained was found to have a porosity of about 64%.

EXAMPLE 3

The process of each of Examples 1 and 2 was repeated, but using the biodegradable microspheres loaded with active ingredient prepared in Reference Example 4. A spongy bio-

- 14 -

degradable materials loaded with the active ingredient was obtained, in each case, having a porosity analogous to that achieved with the unloaded material obtained in Examples 1 and 2.

5 Reference Example 5

The process of Example 1 was repeated, but using the following CO<sub>2</sub> subcritical conditions: 5066 kPa (50 bar), 32°C, 15 min. The material obtained was characterized with a porosity of about 54%.

- 15 -

CLAIMS

1. A method of preparing a biodegradable porous matrix which comprises contacting a biodegradable polymer with a supercritical fluid in a chamber and subsequently reducing 5 the pressure in the chamber to a value below the critical pressure of the fluid in a sharp step.
2. A method according to claim 1 wherein the biodegradable polymer is a polylactide homopolymer or a poly(lactide-co-glycolide) copolymer.
- 10 3. A method according to claim 1 or 2 wherein the biodegradable polymer is in the form of microspheres.
4. A method according to any one of the preceding claims wherein the biodegradable polymer is loaded with an active substance.
- 15 5. A method according to any one of the preceding claims wherein the supercritical fluid is carbon dioxide at a temperature of at least 31.1°C and a pressure of at least 72.8 atmospheres.
6. A surgical implant comprising a biodegradable 20 porous matrix prepared by the method as claimed in claim 1.
7. A controlled release drug delivery system comprising a biodegradable porous matrix prepared by the method as claimed in claim 1 and loaded with an active ingredient.

- 16 -

8. A method of preparing a biodegradable porous matrix substantially as hereinbefore described in any one of Examples 1 to 4.

1/2




FIGURE 1

212




FIGURE 2

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 90/01895

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)<sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.C1. 5 C08J9/18 ; A41K9/16 ; //C08L67:04

## II. FIELDS SEARCHED

Minimum Documentation Searched<sup>7</sup>

Classification System	Classification Symbols	
Int.C1. 5	C08J	A41K

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched<sup>8</sup>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup>

Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	EP,A,113903 (JAPAN STYRENE PAPER CORPORATION) see page 2, line 29 - page 2, line 37; claims 1-5, 9, 10 ---	1-8
Y	US,A,4719246 (DU PONT DE NEMOURS) see column 4, line 65 - column 5, line 3; claims 1-16 ---	1-8
A	EP,A,251631 (ANDERSON) see claims 1-10 ---	1-8
A	EP,A,204476 (INTERNATIONAL MINERALS AND CHEMICALS CORP.) see claims 1-15 ---	1-8
A	US,A,3681270 (DYNAMIT NOBEL A.G.) see claims 1, 2, 6 ---	1-8

<sup>10</sup> Special categories of cited documents : <sup>10</sup><sup>11</sup> "A" document defining the general state of the art which is not considered to be of particular relevance<sup>12</sup> "E" earlier document but published on or after the international filing date<sup>13</sup> "I," document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<sup>14</sup> "O" document referring to an oral disclosure, use, exhibition or other means<sup>15</sup> "P" document published prior to the international filing date but later than the priority date claimed<sup>16</sup> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<sup>17</sup> "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step<sup>18</sup> "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.<sup>19</sup> "&" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

1 31 JANUARY 1991

Date of Mailing of this International Search Report

18 FEB 1991

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

OUDOT R.

ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.

EP 90/01895

SA 41814

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 31/01/91

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-113903	25-07-84	JP-A, B	59127734	23-07-84
		JP-A-	59204630	20-11-84
		JP-A, B	59111823	28-06-84
		US-A-	4464484	07-08-84
US-A-4719246	12-01-88	EP-A-	0272902	29-06-88
		JP-A-	63241024	06-10-88
		US-A-	4766182	23-08-88
		US-A-	4800219	24-01-89
EP-A-251631	07-01-88	US-A-	4832686	23-05-89
EP-A-204476	10-12-86	US-A-	4666704	19-05-87
		AU-B-	590565	09-11-89
		AU-A-	5767286	27-11-86
		JP-A-	61277629	08-12-86
US-A-3681270	01-08-72	None		